Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
NYSE - Nasdaq Real Time Price USD

Bio-Rad Laboratories, Inc. (BIO-B)

Compare
312.05
0.00
(0.00%)
As of February 13 at 10:34:33 AM EST. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,566,500
2,566,500
2,671,262
2,802,249
2,922,545
Cost of Revenue
1,187,600
1,187,600
1,244,316
1,234,919
1,284,449
Gross Profit
1,378,900
1,378,900
1,426,946
1,567,330
1,638,096
Operating Expense
1,109,900
1,109,900
1,089,150
1,092,214
1,137,760
Operating Income
269,000
269,000
337,796
475,116
500,336
Net Non Operating Interest Income Expense
33,100
33,100
51,461
19,886
17,349
Other Income Expense
-2,644,600
-2,644,600
-1,239,404
-5,199,249
4,931,395
Pretax Income
-2,342,500
-2,342,500
-850,104
-4,704,273
5,449,055
Tax Provision
-498,300
-498,300
-212,780
-1,076,738
1,194,798
Net Income Common Stockholders
-1,844,200
-1,844,200
-637,324
-3,627,535
4,254,257
Diluted NI Available to Com Stockholders
-1,844,200
-1,844,200
-637,324
-3,627,535
4,254,257
Basic EPS
-28.08
-65.36
-21.82
-121.79
142.33
Diluted EPS
-28.08
-65.36
-21.82
-121.79
140.56
Basic Average Shares
28,411.75
28,214
29,209
29,785
29,831
Diluted Average Shares
28,411.75
28,214
29,209
29,785
30,208
Total Operating Income as Reported
269,000
269,000
337,796
482,616
500,336
Total Expenses
2,297,500
2,297,500
2,333,466
2,327,133
2,422,209
Net Income from Continuing & Discontinued Operation
-1,844,200
-1,844,200
-637,324
-3,627,535
4,254,257
Normalized Income
239,096.50
239,096.50
293,954
382,859.28
403,384.21
Interest Income
82,000
82,000
100,900
58,000
18,900
Interest Expense
48,900
48,900
49,439
38,114
1,551
Net Interest Income
33,100
33,100
51,461
19,886
17,349
EBIT
-2,293,600
-2,293,600
-800,665
-4,666,159
5,450,606
EBITDA
-2,142,000
-2,142,000
-654,765
-4,528,859
5,588,206
Reconciled Cost of Revenue
1,187,600
1,187,600
1,244,316
1,234,919
1,284,449
Reconciled Depreciation
151,600
151,600
145,900
137,300
137,600
Net Income from Continuing Operation Net Minority Interest
-1,844,200
-1,844,200
-637,324
-3,627,535
4,254,257
Total Unusual Items Excluding Goodwill
-2,646,200
-2,646,200
-1,241,704
-5,201,549
4,930,695
Total Unusual Items
-2,646,200
-2,646,200
-1,241,704
-5,201,549
4,930,695
Normalized EBITDA
504,200
504,200
586,939
672,690
657,511
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-562,903.50
-562,903.50
-310,426
-1,191,154.72
1,079,822.21
12/31/2021 - 9/21/1999

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

S1YK34.SA Stryker Corporation
111.92
0.00%
 
LIVN LivaNova PLC
40.94
-17.29%
 
IART Integra LifeSciences Holdings Corporation
24.91
+12.97%
 
CNMD CONMED Corporation
62.16
+0.31%
 
STE STERIS plc
223.76
+0.04%
 
ITGR Integer Holdings Corporation
126.31
-0.53%
 
CTKB Cytek Biosciences, Inc.
5.05
-3.26%
 
HSCS HeartSciences Inc.
3.3179
-10.81%
 
SNN Smith & Nephew plc
28.03
+6.66%
 
AMIX Autonomix Medical, Inc.
2.8096
-4.11%